Masakatsu Tsurusaki
Overview
Explore the profile of Masakatsu Tsurusaki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
90
Citations
765
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Fujiwara N, Tsurusaki M, et al.
Clin Mol Hepatol
. 2025 Mar;
PMID: 40065709
Background/aims: Previously, we advocated the importance of classifying hepatocellular carcinoma (HCC) based on physiological functions. This study aims to classify HCC by focusing on liver-intrinsic metabolism and glycolytic pathway in...
2.
Urase A, Tsurusaki M, Kozuki R, Kono A, Sofue K, Ishii K
World J Gastroenterol
. 2025 Jan;
31(2):98031.
PMID: 39811504
Background: Focal nodular hyperplasia (FNH)-like lesions are hyperplastic formations in patients with micronodular cirrhosis and a history of alcohol abuse. Although pathologically similar to hepatocellular carcinoma (HCC) lesions, they are...
3.
Tsurusaki M, Sofue K, Murakami T, Tanigawa N
Cancers (Basel)
. 2025 Jan;
17(1.
PMID: 39796729
The liver is supplied by a dual blood flow system consisting of the portal vein and hepatic artery. Imaging techniques for diagnosing hepatocellular carcinoma (HCC) have been developed along with...
4.
Aoki T, Nishida N, Kurebayashi Y, Sakai K, Morita M, Chishina H, et al.
Liver Cancer
. 2024 Jun;
13(3):285-305.
PMID: 38894812
Introduction: Immunotherapy is becoming a promising approach for unresectable-hepatocellular carcinoma (HCC); the anti-tumor response is affected by the tumor microenvironment (TME). Although Wnt/β-catenin mutations are reported to cause non-inflamed phenotype,...
5.
Tsurusaki M, Kozuki R, Urase A
Hepatobiliary Surg Nutr
. 2024 Apr;
13(2):379-381.
PMID: 38617483
No abstract available.
6.
Kotera T, Tsurusaki M, Kozuki R, Urase A, Hirayama A, Ishii K
Interv Radiol (Higashimatsuyama)
. 2024 Mar;
9(1):36-40.
PMID: 38524997
Retroportal artery is one of the communicating arteries between the hepatic artery and the superior mesenteric artery, but it is often a small artery and usually unrecognized. We report a...
7.
Aoki T, Kudo M, Ueshima K, Morita M, Chishina H, Takita M, et al.
Liver Cancer
. 2024 Feb;
13(1):56-69.
PMID: 38344443
Introduction: Programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) signaling blockade is the most effective strategy for the treatment of immune evading hepatocellular carcinoma (HCC). While immune checkpoint inhibitor...
8.
Iwamoto H, Suzuki H, Masuda A, Sakaue T, Nakamura T, Tanaka T, et al.
iScience
. 2024 Feb;
27(2):108797.
PMID: 38303694
Current approved anti-angiogenic drugs (AAD) for hepatocellular carcinoma (HCC) inhibit tumor angiogenesis, but affect the hepatic vasculature resulting in adverse effects. Tumor endothelial cells (TECs) differ from normal endothelial cells....
9.
Ichikawa S, Motosugi U, Sawai Y, Ishida H, Imai Y, Kozaka K, et al.
Hepatol Res
. 2023 Sep;
54(1):43-53.
PMID: 37676063
Aim: To determine risk factors associated with hepatocellular carcinoma (HCC) development following direct-acting antiviral (DAA) therapy. Methods: We enrolled patients with chronic hepatitis C who underwent direct-acting antiviral therapy and...
10.
Tsuchitani T, Kitajima K, Takahashi Y, Yoshida R, Kiada H, Tsurusaki M, et al.
Hell J Nucl Med
. 2023 Aug;
26(2):108-113.
PMID: 37527046
Objective: With single photon emission computed tomography (SPECT)/computed tomography (CT) quantitative examinations, CT-based attenuation correction (CTAC) is considered necessary, though its effect on the quantitative values of an examined area...